XCR1 and neoplasm: Synergy of MATE-expressing virotherapy and checkpoint inhibition led to tumor-free survival of the majority of treated mice associated with an improved CD8/CD4+ T-cell ratio and an elevated frequency of XCR1+ dendritic cells which have been shown to be particularly relevant for the cross presentation of tumor antigen (Bachem et al, 2010).